PuraPharm (HKG:1498) reported HK$21.8 million in attributable loss for the first half of 2025, 17% wider than the HK$18.7 million loss posted a year earlier, according to a Hong Kong bourse filing Tuesday.

Loss per share was HK$0.0552, compared with HK$0.0473 in the prior year.

The medicine company's revenue fell 17% year on year to HK$172.3 million, figures showed.